作者: Georg Kemmler , Christian Humpel , Therese Koal , Kristaps Klavins , Daniele Seppi
DOI: 10.3233/JAD-142319
关键词:
摘要: Alzheimer’s disease (AD) is a severe and chronic neurodegenerative disorder of the brain. The laboratory diagnosis limited to analysis three biomarkers in cerebrospinal fluid (CSF): amyloid-β42 (Aβ42), total tau, phospho-tau-181 (P-tau-181). However, there need find more CSF that can improve sensitivity specificity. aim present study was analyze endogenous small metabolites (metabolome) CSF, which may provide potentially new insights into biochemical processes involved AD. One hundred samples were dichotomized by normal (n = 50) pathological decreased Aβ42 increased tau P-tau-181 levels 50; correlating an AD-like pathology). These analyzed using AbsoluteIDQ® p180 Kit (BIOCRATES Life Sciences), included 40 acylcarnitines, 21 amino acids, 19 biogenic amines, 15 sphingolipids, 90 glycerophospholipids. Our data show two sphingomyelins (SM (d18:1/18:0) SM (d18:1/18:1)), 5 glycerophospholipids (PC aa C32:0, PC C34:1, C36:1, C38:4 C38:6), 1 acylcarnitine (C3-DC-M/C5-OH) significantly altered with “AD-like pathology”. Sphingomyelin proved be specific (76%) sensitive (66%) biomarker defined cut-off 546 nM. Correct diagnoses for out 32 unknown could achieved this value. In conclusion, sphingolipid patients displaying Aβ42, P-tau-181.